Unicycive faces securities litigation as NDA resubmission awaits June PDUFA decision

Filed May 12, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 14, 2025 · ~1 min read

Key Changes

• high

  Securities class action filed in August 2025 alleging material misrepresentations about OLC manufacturing and NDA approval prospects; company filed motion to dismiss in March 2026, with defense costs potentially material to financial statements.

  Legal Proceedings verify on EDGAR →
• high

  FDA accepted NDA resubmission in January 2026 as Class II complete response with PDUFA target date of June 29, 2026, following June 2025 CRL citing single manufacturing vendor compliance deficiency.

  MD&A: Regulatory Update verify on EDGAR →
• high

  Q1 2026 net loss of $12.8M vs. Q1 2025 net income of $0.6M, driven by $4.8M unfavorable warrant liability revaluation; accumulated deficit increased to $140.6M from $100.7M year-over-year.

  MD&A: Financial Results verify on EDGAR →